在意大利背景下如何在家治疗新冠患者：专家意见
How to Treat COVID-19 Patients at Home in the Italian Context: An Expert Opinion.
作者信息
Donno Davide Roberto, Grattagliano Ignazio, Rossi Alessandro, Lora Aprile Pierangelo, Medea Gerardo, Lagolio Erik, Granata Guido, Petrosillo Nicola, Cricelli Claudio
机构信息
Clinical and Research Department for Infectious Diseases, National Institute for Infectious Diseases L. Spallanzani IRCCS, 00149 Rome, Italy.
Italian College of General Practitioners and Primary Care, 50142 Florence, Italy.
出版信息
Infect Dis Rep. 2021 Mar 20;13(1):251-258. doi: 10.3390/idr13010028.
Abstract
The impact of the coronavirus disease (COVID-19), caused by the novel coronavirus SARS-CoV-2, continues to be widespread, with more than 100 million cases diagnosed in more than 220 countries since the virus was first identified in January 2020. Although patients with mild to moderate forms of COVID-19 could be efficiently managed at home, thus reducing the pressure on the healthcare system and minimizing socio-psychological impact on patients, no trial has been proposed, conducted, or even published on COVID-19 home therapy to date. These expert opinions provide indications on the therapeutical at home management of COVID-19 patients, based on the evidence from the literature and on current guidelines.
摘要
由新型冠状病毒SARS-CoV-2引起的冠状病毒病（COVID-19）的影响仍在广泛蔓延，自2020年1月首次发现该病毒以来，220多个国家已诊断出超过1亿例病例。虽然轻症至中症COVID-19患者可以在家中得到有效管理，从而减轻医疗系统的压力并将对患者的社会心理影响降至最低，但迄今为止，尚未有关于COVID-19家庭治疗的试验被提出、开展甚至发表。这些专家意见基于文献证据和现行指南，为COVID-19患者的家庭治疗管理提供了指导。
相似文献
1
How to Treat COVID-19 Patients at Home in the Italian Context: An Expert Opinion.在意大利背景下如何在家治疗新冠患者：专家意见
Infect Dis Rep. 2021 Mar 20;13(1):251-258. doi: 10.3390/idr13010028.
2
Home Management of Children With COVID-19 in the Emilia-Romagna Region, Italy.意大利艾米利亚 - 罗马涅地区新冠病毒感染儿童的居家管理
Front Pediatr. 2020 Oct 23;8:575290. doi: 10.3389/fped.2020.575290. eCollection 2020.
3
Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemic.在新冠疫情前夕，意大利医护人员对新冠病毒感染存在不当的风险认知。
Acta Biomed. 2020 May 14;91(3):e2020040. doi: 10.23750/abm.v91i3.9727.
4
COVID-19 Outbreak in Italy: Protecting Worker Health and the Response of the Italian Industrial Hygienists Association.意大利的 COVID-19 疫情爆发：保护工人健康和意大利工业卫生学家协会的应对措施。
Ann Work Expo Health. 2020 Jul 1;64(6):559-564. doi: 10.1093/annweh/wxaa044.
5
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
6
Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty.COVID-19 大流行期间炎症性肠病患者的实用管理：澳大利亚胃肠病学会炎症性肠病学院专家评论。
Intern Med J. 2020 Jul;50(7):798-804. doi: 10.1111/imj.14889.
7
Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.冠状病毒疾病与妊娠：新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征
Przegl Epidemiol. 2020;74(2):276-289. doi: 10.32394/pe.74.21.
8
Occupational risks for SARS-CoV-2 infection: the Polish experience.职业暴露感染 SARS-CoV-2 的风险：波兰经验。
Int J Occup Med Environ Health. 2020 Oct 20;33(6):781-789. doi: 10.13075/ijomeh.1896.01663. Epub 2020 Jul 22.
9
A Review on Mode of Delivery during COVID-19 between December 2019 and April 2020.2019 年 12 月至 2020 年 4 月期间 COVID-19 期间的分娩方式综述。
Am J Perinatol. 2021 Mar;38(4):332-341. doi: 10.1055/s-0040-1721658. Epub 2020 Dec 7.
10
Primary care management of the coronavirus (COVID-19).冠状病毒病（COVID-19）的基层医疗管理
S Afr Fam Pract (2004). 2020 Mar 31;62(1):e1-e4. doi: 10.4102/safp.v62i1.5115.
引用本文的文献
1
COVID-19 home remedy consumption and perceived effectiveness among adult population in Brunei Darussalam: a PLS-SEM approach.文莱达鲁萨兰国成年人中 COVID-19 家庭疗法的使用和感知效果：PLS-SEM 方法。
BMC Complement Med Ther. 2024 Feb 12;24(1):82. doi: 10.1186/s12906-024-04374-9.
2
Further data on use of NSAIDs for the home-care therapy of COVID-19.关于非甾体抗炎药用于COVID-19家庭护理治疗的更多数据。
Intern Emerg Med. 2023 Aug;18(5):1599-1602. doi: 10.1007/s11739-023-03272-1. Epub 2023 Apr 12.
3
Experiencing COVID-19, home isolation and primary health care: A mixed-methods study.经历 COVID-19、居家隔离和初级卫生保健：一项混合方法研究。
Front Public Health. 2023 Jan 10;10:1023431. doi: 10.3389/fpubh.2022.1023431. eCollection 2022.
4
SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death.SARS-CoV-2 感染（COVID-19）：临床病程、病毒引起的急性呼吸窘迫综合征（ARDS）和死亡原因。
Med Sci (Basel). 2022 Oct 10;10(4):58. doi: 10.3390/medsci10040058.
5
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.家庭作为治疗 COVID-19 的新前沿：抗炎药物的案例。
Lancet Infect Dis. 2023 Jan;23(1):e22-e33. doi: 10.1016/S1473-3099(22)00433-9. Epub 2022 Aug 26.
6
To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care.为了明确 COVID-19 家庭护理患者使用扑热息痛的安全性概况：初级保健中一项真实世界队列研究，包含巢式病例对照分析。
Intern Emerg Med. 2022 Nov;17(8):2237-2244. doi: 10.1007/s11739-022-03054-1. Epub 2022 Jul 30.
7
Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020.阿扎那韦与洛匹那韦治疗新型冠状病毒肺炎感染的疗效比较：一项2020年的回顾性蛋白酶抑制剂对比研究
Caspian J Intern Med. 2022;13(Suppl 3):173-179. doi: 10.22088/cjim.13.0.173.
8
The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.新型冠状病毒肺炎/结核病综合征及从大流行中吸取的经验教训对结核病抗体治疗的启示
Front Immunol. 2022 Feb 15;13:833715. doi: 10.3389/fimmu.2022.833715. eCollection 2022.
9
COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy.门诊环境中COVID-19患者的管理：来自意大利南部的一项基于人群的研究。
J Clin Med. 2021 Dec 23;11(1):51. doi: 10.3390/jcm11010051.
10
Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.COVID-19 早期的家庭药物治疗以预防住院和降低死亡率：是时候提出一个合适的建议了。
Basic Clin Pharmacol Toxicol. 2022 Feb;130(2):225-239. doi: 10.1111/bcpt.13690. Epub 2021 Dec 2.
本文引用的文献
1
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 患者住院期间使用阿奇霉素（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5. Epub 2021 Feb 2.
2
Vitamin D and COVID-19: why the controversy?维生素D与2019冠状病毒病：为何存在争议？
Lancet Diabetes Endocrinol. 2021 Feb;9(2):53. doi: 10.1016/S2213-8587(21)00003-6. Epub 2021 Jan 11.
3
Rationale for azithromycin in COVID-19: an overview of existing evidence.COVID-19 中使用阿奇霉素的理由：现有证据概述。
BMJ Open Respir Res. 2021 Jan;8(1). doi: 10.1136/bmjresp-2020-000806.
4
Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk.厘清维生素D缺乏是否会增加感染新冠病毒的风险。
JAMA. 2021 Jan 26;325(4):329-330. doi: 10.1001/jama.2020.24127.
5
WHO recommends corticosteroids for patients with severe or critical COVID-19.世界卫生组织建议对患有严重或危急 COVID-19 的患者使用皮质类固醇。
Ann Intern Med. 2021 Jan;174(1):JC2. doi: 10.7326/ACPJ202101190-002. Epub 2021 Jan 5.
6
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
7
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
8
Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers.无症状和危重症 COVID-19 患者的维生素 D 水平分析及其与炎症标志物的相关性。
Sci Rep. 2020 Nov 19;10(1):20191. doi: 10.1038/s41598-020-77093-z.
9
Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients.新冠病毒-19：美国食品药品监督管理局批准中和抗体巴尼韦单抗用于非住院患者。
BMJ. 2020 Nov 11;371:m4362. doi: 10.1136/bmj.m4362.
10
Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect".COVID-19 患者重症监护中细菌和真菌感染性血流感染的发生率：令人震惊的“附带效应”。
J Glob Antimicrob Resist. 2020 Dec;23:290-291. doi: 10.1016/j.jgar.2020.10.004. Epub 2020 Oct 29.
Zotero 插件